부산대학교 도서관

Among 13 patients that met IWCLL treatment criteria but did not start alternative therapy, 2 patients were deemed to be unable to tolerate further therapy by treating physician, 5 patients elected not to start alternative therapy, 2 patients died, 1 had a secondary malignancy, and 3 patients were lost to follow up. Disease progression in treatment naïve patients during treatment with ibrutinib is infrequent, but for relapsed patients with high-risk characteristics, progression occurs more frequently, and has been associated with poor survival [[1]]. Initial reports of patients who discontinued ibrutinib therapy for non-relapse reasons demonstrated a median survival of 8 days, however these results were heavily influenced by patients who discontinued therapy secondary to an infectious complication [[4]]. A retrospective review of 56 CLL patients that developed atrial fibrillation while on ibrutinib showed that atrial fibrillation was persistent in 35 of 56 (62%) cases despite treatment and prompted permanent discontinuation of ibrutinib in 26 of 56 (46%) patients [[12]]. [Extracted from the article]